Nichols & Pratt Advisers LLP MA Takes $220,000 Position in Biogen Inc. (BIIB)

Nichols & Pratt Advisers LLP MA bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 702 shares of the biotechnology company’s stock, valued at approximately $220,000.

Other large investors have also recently modified their holdings of the company. Carroll Financial Associates Inc. lifted its position in Biogen by 1.2% during the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after buying an additional 6 shares in the last quarter. RMB Capital Management LLC lifted its position in Biogen by 1.1% during the 1st quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock worth $223,000 after buying an additional 9 shares in the last quarter. New Amsterdam Partners LLC NY lifted its position in Biogen by 0.8% during the 2nd quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock worth $399,000 after buying an additional 11 shares in the last quarter. Alta Capital Management LLC lifted its position in Biogen by 0.8% during the 2nd quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock worth $510,000 after buying an additional 15 shares in the last quarter. Finally, Bienville Capital Management LLC lifted its position in Biogen by 2.2% during the 2nd quarter. Bienville Capital Management LLC now owns 880 shares of the biotechnology company’s stock worth $239,000 after buying an additional 19 shares in the last quarter. Institutional investors own 88.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Nichols & Pratt Advisers LLP MA Takes $220,000 Position in Biogen Inc. (BIIB)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/20/nichols-pratt-advisers-llp-ma-takes-220000-position-in-biogen-inc-biib.html.

BIIB has been the topic of a number of research reports. Vetr downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 target price on the stock. in a research report on Tuesday, August 29th. ValuEngine downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Robert W. Baird restated a “hold” rating and set a $290.00 target price on shares of Biogen in a research report on Friday, August 25th. SunTrust Banks, Inc. restated a “buy” rating and set a $354.00 target price on shares of Biogen in a research report on Tuesday, October 24th. Finally, Mizuho restated a “neutral” rating and set a $319.00 target price (up from $274.00) on shares of Biogen in a research report on Wednesday, September 13th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $341.89.

Biogen Inc. (NASDAQ:BIIB) traded down $3.29 during midday trading on Monday, hitting $310.68. The stock had a trading volume of 210,340 shares, compared to its average volume of 1,509,567. The firm has a market cap of $66,397.40, a P/E ratio of 14.54, a PEG ratio of 1.96 and a beta of 0.72. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. Biogen Inc. has a 12 month low of $244.28 and a 12 month high of $348.84.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.70 by $0.61. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.19 EPS. equities analysts predict that Biogen Inc. will post 22.03 EPS for the current fiscal year.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply